Retrospective analysis of soft tissue injuries treated with allogenic bone marrow derived mesenchymal stem cells

dc.contributor.authorFerraz de Menezes, Rui
dc.contributor.authorMonteiro, Susana
dc.contributor.authorVan de Winkel, Don
dc.contributor.authorDe Bruijn, Marco
dc.contributor.authorLavado, Nuno
dc.contributor.authorBoshuizen, Berit
dc.date.accessioned2022-11-17T17:13:23Z
dc.date.available2022-11-17T17:13:23Z
dc.date.issued2022
dc.description.abstractObjectives: Tendon and ligament pathology has been managed successfully with mesenchymal stem cells from various biological sources. This retrospective study aims to evaluate the re-injury rate of the treatment of tendon and ligament lesions with allogenic bone marrow derived mesenchymal stem cells (BM-MSCs). Methods: Data from horses treated with allogenic BM- MSCs was recovered retrospectively from hospital records. Horses were included if they were solely treated with BM- MSCs, received only one treatment, had no other concur- rent lesion at the time of treatment, and had sufficient information about lameness and ultrasound evaluations. Outcome was evaluated in terms of re-injury within 12 months after treatment. Frequency counts were calcu- lated, and a chi-square test of homogeneity was used to determine whether distribution was identical across differ- ent disciplines and different anatomic structures. Results: Forty-two horses were included: 8 show jum- pers, 15 dressage horses, 15 Standardbreds and 7 leisure horses. There were 22 digital flexor tendons and 20 liga- ment injuries. The overall re-injury rate was 33%. No sta- tistical evidence was found to conclude that re-injury rate was influenced by discipline (p-value = 0.987) or ana- tomic structure (p-value = 0.592). No adverse reactions were observed on the treated horses. Conclusions: The treatment was safe, and re-injury rate was lower than reported when using conventional thera- pies. Our sample suggests that re-injury rate is the same across the different disciplines and anatomic structures. Further studies should be conducted, imposing a larger sample size and a control group.por
dc.identifier.authoremailruidmenezes@gmail.com
dc.identifier.authoremailsosm@uevora.pt
dc.identifier.authoremaildvandewinkel@dierenkliniekwolvega.nl
dc.identifier.authoremailmdebruijn@dierenkliniekwolvega.nl
dc.identifier.authoremailnlavado@isec.pt
dc.identifier.authoremailbboshuizen@dierenkliniekwolvega.nl
dc.identifier.citationScientific Presentation Abstracts: 2022 ECVS 31st Annual Scientific Meeting July 7-9, Porto, Portugal. Veterinary Surgery, 51: O22. https://doi.org/10.1111/vsu.13854por
dc.identifier.doihttps://doi.org/10.1111/vsu.13854por
dc.identifier.scientificarea206por
dc.identifier.urihttps://doi.org/10.1111/vsu.13854
dc.identifier.urihttp://hdl.handle.net/10174/32774
dc.language.isoporpor
dc.peerreviewedyespor
dc.publisherWileypor
dc.rightsopenAccesspor
dc.subjectequinepor
dc.subjectdesmitispor
dc.subjecttendonitispor
dc.subjectallogenic stem cellspor
dc.subjectbone marrowpor
dc.subjectultrassoundpor
dc.titleRetrospective analysis of soft tissue injuries treated with allogenic bone marrow derived mesenchymal stem cellspor
dc.typearticlepor

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Veterinary Surgery - 2022 - - Scientific Presentation Abstracts 2022 ECVS 31st Annual Scientific Meeting July 7‐9 Porto .pdf
Size:
76.42 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
3.89 KB
Format:
Item-specific license agreed upon to submission
Description: